<DOC>
	<DOCNO>NCT00317213</DOCNO>
	<brief_summary>It show rodent model chronic substance abuse associate rigidification cell membrane fluidity due change membrane cholesterol/phospholipids ratio . Upon substance withdrawal membrane undergoes reequilibration ratio , process result acute prolong severe withdrawal syndrome . MBM develop patent , phosphatidic acid-enriched phospholipid platform ( `` LIBERTAL '' ) , suppose facilitate membrane fluidity recovery . The company focus nicotine withdrawal smoking cessation , primary target .</brief_summary>
	<brief_title>Smoking Cessation Assistance With LIBERTAL , A Phospholipid Mixture</brief_title>
	<detailed_description>A randomized , double-blind , dose-finding , phase IIB study Libertal perform 493 volunteer smoker , wish quit . They divide 5 arm : 4 treatment group 0.5 , 1.0 , 2.0 4.0g/day respectively , one placebo , divide BID . Treatment administer one week prior smoke cessation , continue 8 week ( 56 day ) , follow another 4 week without treatment ( day 84 ) . The primary endpoint complete smoke cessation least 28 consecutive day . There 6 on-site visit 4 telephone interview .</detailed_description>
	<criteria>Smokers least 1 year duration Smoking least 10 cigarettes/day Having fail least one previous smoke cessation effort . Without major cardiovascular metabolic disease condition . An uncontrolled major cardiovascular , metabolic , condition condition . Need surgery period participation trial . Any treatment smoking cessation 2 month precede enrollment present trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Smoking</keyword>
	<keyword>Nicotine</keyword>
	<keyword>Withdrawal</keyword>
	<keyword>Phospholipids</keyword>
	<keyword>Cell membrane fluidity</keyword>
	<keyword>Smoking cessation</keyword>
</DOC>